Rheumatoid arthritis-preventive agent for oral intake

a technology of rheumatoid arthritis and oral intake, which is applied in the direction of drug compositions, peptide/protein ingredients, peptide sources, etc., can solve the problems of prescription for such drugs, and achieve the effect of inhibiting arthritis and excellent safety

Inactive Publication Date: 2010-07-01
CALPIS
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]It is an object of the present invention to provide a rheumatoid arthritis inhibitor for oral intake that has an inhibitory effect on arthritis associated with rheumatoid arthritis, gives little concerns for side effects, and is excellent in safety.
[0008]It is another object of the present invention to provide functional food, such as health foods or foods for specified health uses, that may be subjected to daily and regular intake, is excellent in safety, and is expected to have an inhibitory effect on arthritis associated with rheumatoid arthritis.
[0010]According to the present invention, there is also provided functional food comprising, as an active component, a casein hydrolysate comprising free amino acids and peptides obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, or a mixture of free amino acids and peptides contained in said hydrolysate, and having an inhibitory effect on rheumatoid arthritis.
[0013]Containing, as an active component, the particular casein hydrolysate or a mixture of free amino acids and peptides contained in the casein hydrolysate, which are known as a food material, the rheumatoid arthritis inhibitor for oral intake and the functional food according to the present invention are excellent in safety, and may be expected to have an inhibitory effect on arthritis and the like associated with rheumatoid arthritis. In particular, when the active component is made into an agent in the form of powders of tablets and added to functional food or the like, the resulting product may be subjected to daily and regular intake.

Problems solved by technology

However, antirheumatic drugs, such as the conventional immunosuppressants or immunomodulators, have side effects of some kind, so that prescription for such drugs should be restricted to some extent.
However, it is not known to date that milk components or digestion products thereof, which are known as a food material and have sufficiently assured safety, have a RA inhibitory effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rheumatoid arthritis-preventive agent for oral intake

Examples

Experimental program
Comparison scheme
Effect test

production example 1

[0052]1 g of casein derived from cow's milk (manufactured by NIPPON NZMP (Japan) LTD.) was added to 99 g of distilled water adjusted to about 80° C., and the resulting mixture was thoroughly stirred. The pH of the mixture was adjusted to 7.0 with 1N sodium hydroxide solution (manufactured by WAKO PURE CHEMICAL INDUSTRIES, LTD.), and the temperature was adjusted to 20° C., to prepare a substrate solution.

[0053]To this substrate solution, a commercially available enzyme (Sumizyme FP, registered trademark, manufactured by SHIN NIHON CHEMICAL CO., LTD.), which is derived from Aspergillus oryzae and contains at least metal protease, serine protease, neutral protease I, neutral protease II, and leucine amino peptidase, was added at the enzyme / casein ratio of 1 / 25 by weight, and the resulting mixture was reacted at 50° C. for 14 hours. Then the reaction product was autoclaved at 110° C. for 10 minutes to inactivate the enzyme, thereby obtaining a solution of enzymatic hydrolysate of casein...

production example 2

[0064]Lactobacillus helveticus CM4 strain (deposited at International Patent Organism Depositary, National

[0065]Institute of Advanced Industrial Science and Technology, Tsukuba Central 6, 1-1-1 Higashi, Tsukuba-shi, Ibaraki, Japan, under accession number FERM BP-6060 on Aug. 15, 1997) (referred to as CM4 strain hereinbelow) was provided. The CM4 strain has been deposited under the above-mentioned accession number under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, and has already been patented.

[0066]A commercially available skim milk was dissolved in distilled water at 9% (w / w) solid content, subjected to high temperature pasteurization in an autoclave at 105° C. for 10 minutes, and cooled to the room temperature. Then the solution was inoculated with 3% (v / w) of a fermentation liquid of CM4 strain starter (cell count 5×108 cells / ml), and fermented under static conditions at 37° C. for 24 hours to obtain a...

example 2

[0076]The casein enzymatic hydrolysate prepared in Production Example 1 (Example 2) as a test material and Ibuprofen (manufactured by WAKO PURE CHEMICAL INDUSTRIES, LTD.) as a positive control were provided.

[0077]As in Example 1, the adjuvant for sensitization was prepared on the day of sensitization with the adjuvant as will be discussed later.

[0078]Female Lewis rats (SPF) of 8 weeks of age were preliminarily bred for 7 days before subjected to the test. Throughout the preliminary breeding period and the test period, the rats were raised in SPF barrier facilities at a room temperature of 24±3° C. and a relative humidity of 55±15%, with the lighting hours of 7:00 to 19:00 and the air exchange rate of 18 times / hour. The rats were housed 2 to 3 per cage, and all the groups were allowed free access to solid feed (trade name MF, manufactured by ORIENTAL YEAST CO., LTD.) and sterilized deionized water. The rats were identified by picric acid applied on the fur.

[0079]After the preliminary...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
average chain lengthaaaaaaaaaa
swellingaaaaaaaaaa
RA inhibitory effectaaaaaaaaaa
Login to view more

Abstract

There is provided a rheumatoid arthritis inhibitor for oral intake that has an inhibitory effect on rheumatoid arthritis and is excellent in safety. The rheumatoid arthritis inhibitor for oral intake of the present invention contains, as an active component, a casein hydrolysate containing free amino acids and peptides obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, or a mixture of free amino acids and peptides contained in the hydrolysate.

Description

FIELD OF ART[0001]The present invention relates to a rheumatoid arthritis inhibitor for oral intake that contains, as an active component, a particular hydrolysate of animal milk casein having an inhibitory effect on rheumatoid arthritis, such as chronic rheumatoid arthritis, through oral intake, as well as functional food expected to have such an inhibitory effect.BACKGROUND ART[0002]Chronic rheumatoid arthritis (sometimes abbreviated as RA hereinbelow) is an autoimmune disease, wherein inflammation is produced chronically at joints to cause swelling or degeneration due to a cause unknown to date.[0003]It is believed that the inflammation in RA is associated with prostaglandin E (PGE), prostacyclin (PGI), histamine, or kinin such as bradykinin, so that anti-inflammatory agents, typically NSAIDs (nonsteroidal anti-inflammatory drugs), are often prescribed as a first treatment. When such anti-inflammatory agents do not take effect, then antirheumatic drugs are prescribed, such as imm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/01A61P19/02
CPCA61K31/198A61K35/20A61K38/018A23L33/175A23L33/18A23L33/19A61P19/02A61P29/00
Inventor HATORI, MICHIOOHKI, KOHJIHASHIMURA, NAOMIHIROTA, TATSUHIKOOHSAWA, KAZUHITO
Owner CALPIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap